Back to top
more

Innate Pharma (IPHA)

(Delayed Data from NSDQ)

$2.30 USD

2.30
272

+0.14 (6.48%)

Updated Jul 23, 2024 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for IPHA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Innate Pharma SA Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 100 107 142 173 245
Receivables 60 40 22 25 21
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 0 0 0 0 0
Total Current Assets 160 147 164 198 266
Net Property & Equipment 7 9 12 13 13
Investments & Advances 11 37 47 44 41
Other Non-Current Assets 11 15 35 34 19
Deferred Charges 10 9 6 8 1
Intangibles 0 2 52 53 109
Deposits & Other Assets 0 0 0 0 0
Total Assets 199 219 316 351 450
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 18 22 34 34 55
Current Portion Long-Term Debt 10 2 36 2 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 15 19 24 16 79
Total Current Liabilities 43 44 95 52 136
Mortgages 0 0 0 0 0
Deferred Taxes/Income 15 17 36 45 47
Convertible Debt 0 0 0 0 0
Long-Term Debt 34 42 16 19 19
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 52 59 43 56 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 143 162 189 173 206
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 4 4 5 5 4
Capital Surplus 416 400 444 425 414
Retained Earnings -365 -348 -322 -252 -174
Other Equity 1 1 1 0 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 56 57 127 178 244
Total Liabilities & Shareholder's Equity 199 219 316 351 450
Total Common Equity 56 57 127 178 244
Shares Outstanding 80.80 80.20 79.30 78.90 76.50
Book Value Per Share 0.70 0.71 1.60 2.26 3.18

Fiscal Year End for Innate Pharma SA Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 100 -99,999 97
Receivables NA NA 60 NA 61
Notes Receivable NA NA 0 NA NA
Inventories NA NA 0 NA NA
Other Current Assets NA NA 0 NA NA
Total Current Assets NA NA 160 NA 158
Net Property & Equipment NA NA 7 NA 8
Investments & Advances NA NA 11 NA 39
Other Non-Current Assets NA NA 11 NA 1
Deferred Charges NA NA 10 NA 11
Intangibles NA NA 0 NA 1
Deposits & Other Assets NA NA 0 NA 0
Total Assets NA NA 199 NA 217
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 NA NA
Accounts Payable NA NA 18 NA 21
Current Portion Long-Term Debt NA NA 10 NA 6
Current Portion Capital Leases NA NA 0 NA NA
Accrued Expenses NA NA 0 NA NA
Income Taxes Payable NA NA 0 NA NA
Other Current Liabilities NA NA 15 NA 15
Total Current Liabilities NA NA 43 NA 41
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 15 NA 17
Convertible Debt NA NA 0 NA NA
Long-Term Debt NA NA 34 NA 39
Non-Current Capital Leases NA NA 0 NA NA
Other Non-Current Liabilities NA 52 NA 57
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities NA NA 143 NA 154
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA NA
Common Stock (Par) NA NA 4 NA 4
Capital Surplus NA NA 416 NA 416
Retained Earnings NA NA -365 NA -358
Other Equity NA NA 1 NA 1
Treasury Stock NA NA 0 NA NA
Total Shareholder's Equity NA NA 56 NA 63
Total Liabilities & Shareholder's Equity NA NA 199 NA 217
Total Common Equity 0 0 56 0 100,062
Shares Outstanding 80.90 80.80 80.80 80.60 80.40
Book Value Per Share 0.00 0.00 0.70 0.00 1,244.55